Venetoclax after a BTK inhibitor 

If you take venetoclax after a BTK inhibitor, you might wonder how well venetoclax will work for you. Studies have shown the following data: 

• You have an 84.1% chance that you'll achieve a response (CLL is partially or fully reduced).
• The average progression-free survival (PFS) you can expect is 3.6 years. Average PFS refers to the amount of time the cancer has not progressed and/or patients have been alive since the start of treatment.

Venetoclax after chemotherapy and a BTK inhibitor 

If you have received chemotherapy as your first treatment, followed by a covalent BTK inhibitor, and then received treatment with venetoclax, studies show the following: 

• You have a 78.3% chance that you'll achieve a response (CLL is partially or fully reduced).
• The average PFS is 3.7 years.

Despite previously being treated with a BTK inhibitor or chemotherapy, patients who receive venetoclax have high response rates. If you are interested in taking venetoclax after a BTK inhibitor or chemotherapy, reach out to your CLL specialist to evaluate this treatment option.